Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patientswith cryptococcal meningitis and cryptococcosis- Associated immune reconstitution inflammatory syndrome

Journal of Infectious Diseases

Volumn 208, Issue 10, 2013, Pages 1604-1612

  Chang, Christina C ^a,b,c,g   Omarjee, Saleha ^g,h   Lim, Andrew ^e   Spelman, Tim ^d   Gosnell, Bernadett I ⁱ   Carr, William H ^j   Elliott, Julian H ^a,b   Moosa, Mohamed Yunus S ⁱ   Ndung'u, Thumbi ^g,h   French, Martyn A ^e,f   Lewin, Sharon R ^a,b,c  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c Centre for Biomedical Research   (Australia)

^d BURNET INSTITUTE   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f ROYAL PERTH HOSPITAL   (Australia)

^g Doris Duke Medical Research Institute   (South Africa)

^h UNIVERSITY OF KWAZULU NATAL   (South Africa)

ⁱ UNIVERSITY OF KWAZULU NATAL   (South Africa)

^j CITY UNIVERSITY OF NEW YORK   (United States)

more..

Author keywords

Chemokines; Cryptococcus; Hiv; Immune restoration disease

Indexed keywords

AMPHOTERICIN; ANTIRETROVIRUS AGENT; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; FLUCONAZOLE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCOSIS ASSOCIATED IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION;

CHEMOKINES; CRYPTOCOCCUS; HIV; IMMUNE RESTORATION DISEASE;

ADULT; ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; MENINGITIS, CRYPTOCOCCAL; PROSPECTIVE STUDIES; RECEPTORS, CHEMOKINE;

EID: 84888589746     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit388     Document Type: Article

References (38)

1. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23:525-30.
2. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: A systematic review and metaanalysis. Lancet Infect Dis 2010; 10:251-61.
3. Galea I, Bechmann I, Perry VH. What is immune privilege (not)? Trends Immunol 2007; 28:12-8.
4. Lortholary O, Improvisi L, Rayhane N, et al. Cytokine profiles of AIDS patients are similar to those of mice with disseminated Cryptococcus neoformans infection. Infect Immun 1999; 67:6314-20.
5. Sallusto F, Impellizzieri D, Basso C, et al. T-cell trafficking in the central nervous system. Immunol Rev 2012; 248:216-27.
6. Qin S, Rottman JB, Myers P, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 1998; 101:746-54.
7. Groom JR, Luster AD. CXCR3 in T cell function. Exp Cell Res 2011; 317:620-31.
8. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011; 89:207-15.
9. Sorce S, Myburgh R, Krause KH. The chemokine receptor CCR5 in the central nervous system. Prog Neurobiol 2011; 93:297-311.
10. Huffnagle GB, McNeil LK, McDonald RA, et al. Cutting edge: role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J Immunol 1999; 163:4642-6.
11. Takeshita Y, Ransohoff RM. Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev 2012; 248:228-39.
12. Savarin-Vuaillat C, Ransohoff RM. Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? Neurotherapeutics 2007; 4:590-601.
13. Christo PP, Vilela MC, Bretas TL, et al. Cerebrospinal fluid levels of chemokines in HIV infected patients with and without opportunistic infection of the central nervous system. J Neurol Sci 2009; 287:79-83.
14. Chang CC, Dorasamy AA, Gosnell BI, et al. Clinical and mycological predictors of cryptococcosis-associated Immune reconstitution inflammatory syndrome. AIDS 2013; 27:2089-99.
15. Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis 2010; 10: 791-802.
16. Chang CC, Lim A, Omarjee S, et al. Cryptococcosis-IRIS is associated with lower Cryptococcus-specific IFN-γ responses before antiretroviral therapy but not higher T-cell responses during therapy. J Infect Dis. 2013; 208:898-906.
17. Christensen JE, Nansen A, Moos T, et al. Efficient T-cell surveillance of the CNS requires expression of the CXC chemokine receptor 3. J Neurosci 2004; 24:4849-58.
18. Muller M, Carter S, Hofer MJ, Campbell IL. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity- A tale of conflict and conundrum. Neuropathol Appl Neurobiol 2010; 36:368-87.
19. Chen X, Mihalic J, Deignan J, et al. Discovery of potent and specific CXCR3 antagonists. Bioorg Med Chem Lett 2012; 22:357-62.
20. Jenh CH, Cox MA, Cui L, et al. A selective and potent CXCR3 antagonist SCH 546738 attenuates the development of autoimmune diseases and delays graft rejection. BMC Immunol 2012; 13:2.
21. Liu M, Guo S, Hibbert JM, et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 2011; 22:121-30.
22. Uicker WC, McCracken JP, Buchanan KL. Role of CD4+ T cells in a protective immune response against Cryptococcus neoformans in the central nervous system. Med Mycol 2006; 44:1-11.
23. Elovaara I, Muller KM. Cytoimmunological abnormalities in cerebrospinal fluid in early stages of HIV-1 infection often precede changes in blood. J Neuroimmunol 1993; 44:199-204.
24. Martin-Blondel G, Alvarez M, Delobel P, et al. Toxoplasmic encephalitis IRIS in HIV-infected patients: A case series and review of the literature. J Neurol Neurosurg Psychiatry 2011; 82:691-3.
25. Gray F, Bazille C, Adle-Biassette H, Mikol J, Moulignier A, Scaravilli F. Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 2005; 11(Suppl 3):16-22.
26. Boulware DR, Bonham SC, Meya DB, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J Infect Dis 2010; 202:962-70.
27. Siddiqui AA, Brouwer AE, Wuthiekanun V, et al. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol 2005; 174:1746-50.
28. Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F, Dromer F. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun 2009; 77: 120-7.
29. Barber DL, Andrade BB, Sereti I, Sher A. Immune reconstitution inflammatory syndrome: The trouble with immunity when you had none. Nat Rev Microbiol 2012; 10:150-6.
30. Martin-Garcia J, Kolson DL, Gonzalez-Scarano F. Chemokine receptors in the brain: Their role in HIV infection and pathogenesis. AIDS 2002; 16:1709-30.
31. Ansari AW, Heiken H, Meyer-Olson D, Schmidt RE. CCL2: A potential prognostic marker and target of anti-inflammatory strategy in HIV/AIDS pathogenesis. Eur J Immunol 2011; 41:3412-8.
32. Okamoto M, Fuchigami M, Suzuki T, Watanabe N. A novel C-C chemokine receptor 2 antagonist prevents progression of albuminuria and atherosclerosis in mouse models. Biol Pharm Bull 2012; 35:2069-74.
33. Subasinghe NL, Lanter J, Markotan T, et al. A novel series of N-(azetidin- 3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists. Bioorg Med Chem Lett 2013; 23:1063-9.
34. Gathe J, Cade J, DeJesus E, et al. Week 24 primary analysis of cenicriviroc vs efavirenz, in combination with FTC/TDF, in treatment-naive HIV-1 infected adults with CCR5-tropic virus (study 652-2-202; NCT01338883). In: Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013; Atlanta, Georgia.
35. Sierra-Madero J, Tierney A, Rassool M, et al. Efficacy and safety of maraviroc to prevent immune reconstitution inflammatory syndrome in high-risk subjects initiating ART: 24-week results of a randomized, placebo-controlled trial. In: Conference on Retroviruses and Opportunistic Infections, 2013; Atlanta, Georgia.
36. Angel TE, Jacobs JM, Spudich SS, et al. The cerebrospinal fluid proteome in HIV infection: change associated with disease severity. Clin Proteomics 2012; 9:3.
37. Burdo TH, Weiffenbach A, Woods SP, Letendre S, Ellis RJ, Williams KC. Elevated sCD163 is a marker of neurocognitive impairment in HIV infection. AIDS 2013; 27:1387-1395.
38. Price RW, Epstein LG, Becker JT, et al. Biomarkers of HIV-1 CNS infection and injury. Neurology 2007; 69:1781-8.